Suppr超能文献

富含半胱氨酸的 LIM 仅蛋白 4(CRP4)促进载脂蛋白 E 小鼠模型的动脉粥样硬化形成。

Cysteine-Rich LIM-Only Protein 4 (CRP4) Promotes Atherogenesis in the ApoE Mouse Model.

机构信息

Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, 72076 Tübingen, Germany.

Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, 72076 Tübingen, Germany.

出版信息

Cells. 2022 Apr 17;11(8):1364. doi: 10.3390/cells11081364.

Abstract

Vascular smooth muscle cells (VSMCs) can switch from their contractile state to a synthetic phenotype resulting in high migratory and proliferative capacity and driving atherosclerotic lesion formation. The cysteine-rich LIM-only protein 4 (CRP4) reportedly modulates VSM-like transcriptional signatures, which are perturbed in VSMCs undergoing phenotypic switching. Thus, we hypothesized that CRP4 contributes to adverse VSMC behaviours and thereby to atherogenesis in vivo. The atherogenic properties of CRP4 were investigated in plaque-prone apolipoprotein E (ApoE) and CRP4 double-knockout (dKO) as well as ApoE-deficient CRP4 wildtype mice. dKO mice exhibited lower plaque numbers and lesion areas as well as a reduced content of α-smooth muscle actin positive cells in the lesion area, while lesion-associated cell proliferation was elevated in vessels lacking CRP4. Reduced plaque volumes in dKO correlated with significantly less intra-plaque oxidized low-density lipoprotein (oxLDL), presumably due to upregulation of the antioxidant factor peroxiredoxin-4 (PRDX4). This study identifies CRP4 as a novel pro-atherogenic factor that facilitates plaque oxLDL deposition and identifies the invasion of atherosclerotic lesions by VSMCs as important determinants of plaque vulnerability. Thus, targeting of VSMC CRP4 should be considered in plaque-stabilizing pharmacological strategies.

摘要

血管平滑肌细胞(VSMCs)可以从收缩状态转变为合成表型,从而具有高迁移和增殖能力,并驱动动脉粥样硬化病变的形成。据报道,富含半胱氨酸的 LIM 仅蛋白 4(CRP4)调节 VSMC 样转录特征,而在经历表型转换的 VSMCs 中,这些特征受到干扰。因此,我们假设 CRP4 有助于不良的 VSMC 行为,从而有助于体内动脉粥样硬化的发生。在动脉粥样硬化易感性的载脂蛋白 E(ApoE)和 CRP4 双敲除(dKO)以及 ApoE 缺陷型 CRP4 野生型小鼠中研究了 CRP4 的动脉粥样硬化特性。dKO 小鼠的斑块数量和病变面积较低,病变区域中α-平滑肌肌动蛋白阳性细胞的含量减少,而缺乏 CRP4 的血管中病变相关的细胞增殖增加。dKO 小鼠中斑块体积的减少与斑块中氧化型低密度脂蛋白(oxLDL)的含量显著降低相关,这可能是由于抗氧化因子过氧化物酶 4(PRDX4)的上调。本研究确定 CRP4 是一种新的促动脉粥样硬化因子,它促进斑块 oxLDL 的沉积,并确定 VSMCs 对动脉粥样硬化病变的侵袭是斑块易损性的重要决定因素。因此,在斑块稳定化的药理学策略中应考虑针对 VSMC CRP4 的靶向治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3aed/9032522/c2f2964baeff/cells-11-01364-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验